BioHarvest Sciences Inc.
CNVCF · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.39 | 0.44 | -0.01 |
| FCF Yield | -2.47% | -2.70% | -2.02% | -4.22% |
| EV / EBITDA | -57.10 | 2,162.59 | -77.21 | -17.19 |
| Quality | ||||
| ROIC | -12.30% | -9.23% | -18.79% | -26.97% |
| Gross Margin | 56.80% | 51.47% | 56.19% | 50.73% |
| Cash Conversion Ratio | 0.65 | 1.39 | 0.24 | 0.41 |
| Growth | ||||
| Revenue 3-Year CAGR | 80.98% | 87.31% | 85.39% | 82.00% |
| Free Cash Flow Growth | 14.82% | -48.11% | 45.21% | -128.92% |
| Safety | ||||
| Net Debt / EBITDA | -4.53 | 108.75 | -4.31 | -3.08 |
| Interest Coverage | -3.58 | -4.70 | -0.28 | -4.24 |
| Efficiency | ||||
| Inventory Turnover | 0.89 | 1.14 | 0.87 | 0.90 |
| Cash Conversion Cycle | -11.72 | -22.70 | 44.93 | 46.86 |